- Home
- NIVF vs OGEN Comparison
NIVF vs OGEN Comparison
Compare NIVF & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- OGEN
- Stock Information
- Founded
- NIVF 2011
- OGEN 1996
- Country
- NIVF Thailand
- OGEN United States
- Employees
- NIVF N/A
- OGEN 5
- Industry
- NIVF
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- OGEN Health Care
- Exchange
- NIVF NYSE
- OGEN Nasdaq
- Market Cap
- NIVF 2.1M
- OGEN 2.5M
- IPO Year
- NIVF N/A
- OGEN N/A
- Fundamental
- Price
- NIVF $1.05
- OGEN $4.13
- Analyst Decision
- NIVF
- OGEN
- Analyst Count
- NIVF 0
- OGEN 0
- Target Price
- NIVF N/A
- OGEN N/A
- AVG Volume (30 Days)
- NIVF 9.1M
- OGEN 656.3K
- Earning Date
- NIVF 01-01-0001
- OGEN 08-08-2025
- Dividend Yield
- NIVF N/A
- OGEN N/A
- EPS Growth
- NIVF N/A
- OGEN N/A
- EPS
- NIVF N/A
- OGEN N/A
- Revenue
- NIVF $5,433,375.00
- OGEN N/A
- Revenue This Year
- NIVF N/A
- OGEN N/A
- Revenue Next Year
- NIVF N/A
- OGEN N/A
- P/E Ratio
- NIVF N/A
- OGEN N/A
- Revenue Growth
- NIVF 5.79
- OGEN N/A
- 52 Week Low
- NIVF $1.00
- OGEN $3.12
- 52 Week High
- NIVF $656.00
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- NIVF 33.99
- OGEN 47.04
- Support Level
- NIVF $1.00
- OGEN $3.41
- Resistance Level
- NIVF $6.13
- OGEN $4.85
- Average True Range (ATR)
- NIVF 0.17
- OGEN 0.58
- MACD
- NIVF -0.01
- OGEN 0.01
- Stochastic Oscillator
- NIVF 9.35
- OGEN 42.49
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.